This proposal proposes to continue operations and maintenance of the OCG (ocg.cancer.gov) Data Coordinating Center (DCC) to accept, QC, and display data and data types generated by the TARGET, CGCI, CTD2 and other cancer genomics and translation projects. The primary focus of the TARGET and CGCI Initiatives remain identifying genomic alterations that offer pathways to novel therapeutic interventions that may lead to more effective treatments for cancers. NCI-CBIIT provides informatics support for the OCG programs. The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative focuses to rapidly identify potential therapeutic targets in childhood cancers so that new, more effective treatments can be developed in shorter time and ultimately bring new hope to children and their families who face the devastating burden of these diseases. The TARGET Initiative (is focused on identifying therapeutic targets as well as prognostic and diagnostic markers in multiple childhood cancers. The initiative includes the study of high-risk Acute Lymphoblastic Leukemia (ALL), neuroblastoma (NBL), high-risk and treatment refractory Acute Myeloid Leukemia (AML), osteosarcoma (OS), and kidney tumors (including high risk Wilms tumor). These cancers were the chosen for study because of their prevalence among children, the inadequacy of current treatment options, the ongoing NCI-supported efforts to molecularly characterize these cancers, and the availability of clinically annotated, high-quality human tissue collections that met TARGET's strict scientific, technical, and ethical requirements. In the coming year, TARGET will include validation cohorts and other studies. The Cancer Genome Characterization Initiative (CGCI) supports cutting-edge genomics research on rare cancers. Researchers develop and apply advanced sequencing and other genome-based methods to identify novel genetic abnormalities in tumors. The extensive genetic profiles generated by CGCI may inform better cancer diagnosis and treatment. CGCI is another OCG program. CGCI focuses Burkitt Lymphoma and HIV+ Tumor Molecular Characterization Project (HTMCP). Previous projects included early stage Lung Cancers, Medulloblastoma, and Non-Hodgkin Lymphoma. The goal of the Burkitt Lymphoma Genome Sequencing Project (BLGSP) is to explore potential genetic changes in patients with Burkitt lymphoma that could lead to better prevention, detection, and treatment of this rare and aggressive cancer. The OCG, along with the Office of HIV and AIDS Malignancies (OHAM), initiated the HTMCP to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients. The data generated by these projects are stored at the DCC. Cancer Target Discovery and Development (CTD²) initiative bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use...